Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05470725 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Pharmacokinetics of CIN-107 in Subjects With Varying Degrees of Renal Function
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT05470725 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 33 participants.
The verdict
NCT05470725, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
This is a Phase 1, open-label, parallel-group study in subjects with varying degrees of renal function to assess the safety, tolerability, and Pharmacokinetics of a single 10 mg oral dose of CIN-107.
Interventions
- DRUG CIN-107
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2021-01-12 |
| Est. Completion | 2021-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05470725
The ClinicalTrials.gov registry entry for NCT05470725 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CIN-107 is the first listed.
NCT05470725 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05470725 about?
NCT05470725 is a clinical study titled "Study to Evaluate the Pharmacokinetics of CIN-107 in Subjects With Varying Degrees of Renal Function". This is a Phase 1, open-label, parallel-group study in subjects with varying degrees of renal function to assess the safety, tolerability, and Pharmacokinetics of a single 10 mg oral dose of CIN-107.
What is the current status of trial NCT05470725?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2021-01-12. Estimated completion is 2021-04-30.
What interventions are being tested in trial NCT05470725?
The interventions under investigation include: CIN-107 (DRUG).
Who is sponsoring clinical trial NCT05470725?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.